TME Pharma NVXPAR:ALTME -3.45% Days Payable is 0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, TME Pharma NV ranks worse than 142653.21% on this metric.
The historical rank and industry rank for TME Pharma NV's Days Payable or its related term are showing as below:
During the past 12 years, TME Pharma NV's highest Days Payable was 574.89. The lowest was 455.98. And the median was 502.49.
XPAR:ALTME's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
TME Pharma NV's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
TME Pharma NV Days Payable Related Terms
TME Pharma NV Days Payable Historical Data
* Premium members only.
The historical data trend for TME Pharma NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALTME vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, TME Pharma NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's Days Payable distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TME Pharma NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TME Pharma NV (XPAR:ALTME) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TME Pharma NV and its competitors. Over the past decade, TME Pharma NV's Days Payable has ranged from 455.98 to 574.89. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 701 companies in the Biotechnology industry.
Is TME Pharma NV's Days Payable too high?
TME Pharma NV's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 455.98 to a high of 574.89. Based on the distribution chart, TME Pharma NV ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 701 companies for Days Payable. This places TME Pharma NV in the lower half of its industry. The industry median Days Payable is 112.84. Historically, TME Pharma NV's own Days Payable has ranged from 455.98 to 574.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TME Pharma NV and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTME has been successfully added to your 